MONTGOMERY, Texas--(BUSINESS WIRE)--Endovasc, Inc. - (OTCBB: EVSC),
a Business Development Company focused on acquiring and investing in
companies engaged in the development of innovative cardiovascular and
metabolic drugs as well as nutraceutical supplements, confirmed that it
has received a letter from the Securities and Exchange Commission (SEC),
and intends to respond promptly to the queries raised by the SEC.
About Endovasc, Inc.
Endovasc, Inc. is focused on investing in private companies that develop
and commercialize drug candidates in the areas of cardiovascular and
metabolic medicine. Endovasc is organized as a business development
company, and has invested in the following subsidiaries: Liprostin Inc.,
which holds the intellectual property for a liposomal based treatment to
increase circulation and reduce leg pain in patients suffering from
vascular disease; Prostent, Inc., which is developing a stent coating
technology; and Nutraceutical Development Corporation, which has
developed marketed technology to increase muscle mass.
For more information about Endovasc, please visit www.endovasc.com.
Safe Harbor Statement
The foregoing statements are made under the "Safe Harbor" Private
Securities Litigation Reform Act of 1995 and may contain forward-looking
statements that involve risks and uncertainties that may not be evident
at the time of this release.
